Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis

Basit Öğe Kaydı
dc.contributor.authorDuran, Arzu
dc.contributor.authorKobak, Senol
dc.contributor.authorSen, Nazime
dc.contributor.authorAktakka, Seniha
dc.contributor.authorAtabay, Tennur
dc.contributor.authorOrman, Mehmet
dc.date.accessioned2019-10-27T22:58:24Z
dc.date.available2019-10-27T22:58:24Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractCalprotectin is one of the major antimicrobial S100 leucocyte proteins. Serum calprotectin levels are associated with certain inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. The aim of this study was to investigate serum and fecal calprotectin levels in patients with ankylosing spondylitis (AS) and show their potential relations to the clinical findings of the disease. Fifty-one patients fulfilling the New York criteria of AS and 43 healthy age- and gender-matched volunteers were included in the study. Physical and locomotor system examinations were performed and history data were obtained for all patients. Disease activity parameters were assessed together with anthropometric parameters. Routine laboratory examinations and genetic testing (HLA-B-27) were performed. Serum calprotectin levels and fecal calprotectin levels were measured by an enzyme-linked immunosorbent assay. The mean age of the patients was 41.5 years, the mean duration of the disease was 8.6 years, and the delay in diagnosis was 4.2 years. Serum calprotectin levels were similar in both AS patients and in the control group (p=0.233). Serum calprotectin level was correlated with Bath AS disease activity index (BASDAI) and Bath AS functional index (BASFI) (p=0.001, p=0.002, respectively). A higher level of fecal calprotectin was detected in AS patients when compared with the control group. A statistically significant correlation between fecal calprotectin level and BASDAI, BASFI, C-reactive protein and Erythrocyte sedimentation rate were detected (p=0.002, p=0.005, p=0.001, p=0.002, respectively). The results indicated that fecal calprotectin levels were associated with AS disease findings and activity parameters. Calprotectin is a vital disease activity biomarker for AS and may have an important role in the pathogenesis of the disease. Multi-centered prospective studies are needed in order to provide further insight.en_US
dc.identifier.endpage74en_US
dc.identifier.issn1512-8601
dc.identifier.issn1840-4812
dc.identifier.issue1en_US
dc.identifier.pmid26773186en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage71en_US
dc.identifier.urihttps://hdl.handle.net/11454/51536
dc.identifier.volume16en_US
dc.identifier.wosWOS:000369625200012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevoen_US
dc.relation.ispartofBosnian Journal of Basic Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnkylosing spondylitisen_US
dc.subjectcalprotectinen_US
dc.subjectdisease activityen_US
dc.titleFecal calprotectin is associated with disease activity in patients with ankylosing spondylitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu